Stepping-stones to the further advancement of androgen-deprivation therapy for prostate cancer (Q36381291)

13 August 2017

1 reference

title

Stepping-stones to the further advancement of androgen-deprivation therapy for prostate cancer (English)

1 reference

13 August 2017

Tsutomu Nishiyama

1

1 reference

13 August 2017

Kazuya Suzuki

2

1 reference

13 August 2017

Kazutoshi Yamana

3

1 reference

13 August 2017

Etsuko Tonegawa

4

1 reference

13 August 2017

Koichi Wako

5

1 reference

13 August 2017

Kota Takahashi

6

1 reference

13 August 2017

1 February 2006

1 reference

Expert Review of Anticancer Therapy

13 August 2017

1 reference

13 August 2017

6

1 reference

13 August 2017

2

1 reference

13 August 2017

259-268

1 reference

Endocrine treatment in prostate cancer

13 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.259

Gonadotropin-releasing hormone agonists in the treatment of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.259

Mechanisms of endocrine therapy-responsive and -unresponsive prostate tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.259

Antiandrogens in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.259

Hormones and prostate cancer: current perspectives and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.259

Prospective study of sex hormone levels and risk of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.259

Sex steroid hormones and the androgen receptor gene CAG repeat and subsequent risk of prostate cancer in the prostate-specific antigen era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.259

Endogenous sex hormones and prostate cancer: a quantitative review of prospective studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.259

Occult prostate cancer in men with low serum testosterone levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.259

High-grade prostate cancer is associated with low serum testosterone levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.259

Association between prostate cancer and serum testosterone levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.259

Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.259

Testosterone as a predictor of pathological stage in clinically localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.259

Low serum testosterone levels are associated with positive surgical margins in radical retropubic prostatectomy: hypogonadism represents bad prognosis in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.259

Sex steroid hormone metabolism and prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.259

Adrenal steroids in human prostatic cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.259

Differential expression of 17beta-hydroxysteroid dehydrogenase isozyme genes in prostate cancer and noncancer tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.259

The influence of finasteride on the development of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.259

Prevention of prostate cancer with finasteride: US/European perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.259

Androgen receptor in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.259

High level of androgen receptor is associated with aggressive clinicopathologic features and decreased biochemical recurrence-free survival in prostate: cancer patients treated with radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.259

Androgen receptor levels in prostate cancer epithelial and peritumoral stromal cells identify non-organ confined disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.259

A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.259

Androgen-induced differentiation and tumorigenicity of human prostate epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.259

The influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.259

Endogenous steroid levels in the human prostate from birth to old age: a comparison of normal and diseased tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.259

Three-month treatment with a long-acting gonadotropin-releasing hormone agonist of patients with benign prostatic hyperplasia: effects on tissue androgen concentration, 5 alpha-reductase activity and androgen receptor content

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.259

Comparison of residual C-19 steroids in plasma and prostatic tissue of human, rat and guinea pig after castration: unique importance of extratesticular androgens in men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.259

The adrenal androgen androstenediol is present in prostate cancer tissue after androgen deprivation therapy and activates mutated androgen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.259

A controlled trial of leuprolide with and without flutamide in prostatic carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.259

Goserelin acetate and flutamide versus bilateral orchiectomy: a phase III EORTC trial (30853). EORTC GU Group and EORTC Data Center

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.259

Maximum androgen blockade in advanced prostate cancer: a meta-analysis of published randomized controlled trials using nonsteroidal antiandrogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.259

Maximum androgen-blockade with medical or surgical castration in advanced prostate cancer: A meta-analysis of nine published randomized controlled trials and 4128 patients using flutamide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.259

Combined androgen blockade with nonsteroidal antiandrogens for advanced prostate cancer: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.259

Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.259

A re-assessment of the role of combined androgen blockade for advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.259

Combined androgen blockade: the case for bicalutamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.259

The development of androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.259

Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.259

Mechanisms of the development of androgen independence in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.259

Molecular determinants of resistance to antiandrogen therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.259

Andropause: Symptom Management for Prostate Cancer Patients Treated With Hormonal Ablation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.259

Influence of hot flashes on quality of life in patients with prostate cancer treated with androgen deprivation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.259

The influence of androgen deprivation therapy on metabolism in patients with prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.259

Androgen deprivation therapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.259

Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.259

Finasteride and bicalutamide as primary hormonal therapy in patients with advanced adenocarcinoma of the prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.259

Treatment of localized prostate cancer with intermittent triple androgen blockade: preliminary results in 110 consecutive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.259

Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.2.259

21 January 2018

Identifiers

DOI

10.1586/14737140.6.2.259

1 reference

13 August 2017

1 reference